NEK6

Across TCGA pan-cancer cohorts, NEK6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NEK6 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NEK6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NEK6 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and LUAD are the cancer types where NEK6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.582	0.899	<.001	35	view →
LSCC	DFS	Quartile	II,III,IV	0.483	0.851	.013	13	view →
LUAD	OS	Tertile	II,III,IV	0.419	0.770	.028	2	view →
HNSC	DFS	Tertile	II,III,IV	0.560	0.760	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NEK6–CCRCC (DFS)

Open the CCRCC breakdown →